Funding for this research was provided by:
Received: 8 February 2022
Accepted: 9 September 2022
First Online: 24 September 2022
: Ethical approvals by the Ethics Committee of the Medical Faculty at the University of Heidelberg (AFmu-199/2020; 24th June 2021) and Ethics Committee of the Medical Faculty at the Johannes Kepler University of Linz (ECS 1097/2021; 26th May 2021) were obtained. Written informed consent is obtained from all participants. Furthermore, the DEGRO expert panel reviewed the radiation regimen to rule out that permission of radiation administered would have to be requested from the BfS (Federal office of radiation protection; “Anfrage 172 / 15.04.2020”). Additionally, the Paul Ehrlich Institute (competent authority for approval of clinical trials using medicinal products for human use in Germany) approved the study (no. 4049/03, 16th March 2021).
: Not applicable, as no individual patient data are contained in this manuscript.
: There has been no financial support for this work that could have influenced its outcome. The TREASURE trial receives funding from Roche Pharma AG. However, Roche Pharma AG has not been involved in study design, data collection, management, data analysis and interpretation, or in the decision to submit this protocol for publication. All authors declare that there are no competing conflicts of interest.